Objective:To investigate effects and safety of docetaxel/cisplatin given as first-line chemotherapy every 4 weeks in unresectable non-small cell lung cancer (NSCLC). Methods:Thirty-nine patients (male/female: 21/18) with unresectable NSCLC were enrolled for the study. They were at the ages ranging from 33 to 79 years old with ECOG PS of 0~2. Docetaxel and cisplatin were administered at the dose of 75 mg/m 2 on day 1 intravenously every 4 weeks. The responses and toxicity of chemotherapy were evaluated every two cycles and survival was followed up.Results:In the 38 evaluable cases, partial response (PR) and complete response (CR) were observed in 21 cases and 1 case, respectively with overall response rate of 58%. The response rate in the cases with ECOG PS of 0~1 was significantly higher than in those with ECOG PS of 2. Median survival time was 14 months and 1 year-survival rate was 61 5%. The toxicities were mild, including 40% Grade 3 or 4 leucopenia. One case died from leucopenia infection soon after 1 cycle of chemotherapy. Conclusion:Four-week regimen of docetaxel/cisplatin was effective and safe as the first line treatment for the unresectable NSCLC patients.